Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: Cancer and Leukemia Group B study 10002
- Citation:
- Br J Haematol vol 165 (1) 102-111
- Year:
- 2014
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 3
- Parents:
- 474
- Children:
- None
- Pharmas:
- Grants:
- U10 CA047577, U10 CA032291, CA33601, CA11789, U10 CA077658, CA77406, CA47577, CA41287, U10 CA035279, CA03927, U10 CA031946, U10 CA033601, CA59518, U10 CA180821, U10 CA059518, CA35279, U10 CA045418, CA16450, U10 CA041287, U10 CA047559, CA08025, CA74811, U10 CA180882, P30 CA016058, CA47559, CA47642, CA45418, U10 CA074811, CA77658, U10 CA180838, U10 CA047642, CA31983, CA31946, U10 CA003927
- Corr. Author:
- Authors:
- David A. Rizzieri Jeffrey L. Johnson John C. Byrd Gerard Lozanski Kristie A. Blum Bayard L. Powell Thomas C. Shea Sreenivasa Nattam Eva Hoke Bruce D. Cheson Richard A. Larson
- Networks:
- Study
- CALGB-10002
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Burkitt Leukaemia, Burkitt Lymphoma, Chemo-immunotherapy, rituximab